Why This Analyst Says Robinhood Is More Than ...

Despite a rough past week for the healthcare sector, pharmaceuticals and biotech stocks have outperformed the S&P 500 this year. Investors have gotten excited over cancer treatment breakthroughs for Moderna, Merck and Revolution Medicines—plus regulatory shakeups at the FDA. But ...  Show more

On this week’s episode of WSJ’s Take On the Week, host Miriam Gottfried and guest host Aaron Back, editor of WSJ’s Heard on the Street, preview the upcoming employment and inflation releases in advance of the Federal Open Market Committee’s September policy meeting. They analyze ...  Show more

For YMB listeners, here’s a special presentation of WSJ’s Take On the Week: Co-hosts Gunjan Banerji, lead writer for Live Markets, and Telis Demos, Heard on the Street’s banking and money columnist, cut through the noise and dive into markets, the economy, and finance—the big tra ...  Show more

Carl Quintanilla, Jim Cramer and David Faber led off the show with a look at Apple: Shares rose after the company posted better-than-expected quarterly results, including an 11% jump in revenue. The anchors reacted to what Apple CEO Tim Cook told CNBC about improvement in the sup ...  Show more

Here's the top stories from the financial sector this week. Intro: In this episode of Industry Focus: Financials, host Jason Moser and Fool.com contributor Matt Frankel, CFP, dig into the first earnings report Robinhood (NASDAQ: HOOD) has issued as a public company. Also, we rece ...  Show more

Send us Fan MailNo other app deserves more credit for making stock trading accessible to the average Joe than Robinhood. It's also a company that has made national news headlines in 2021 - but not for the reasons you want. With all the recent press, we've been getting questions l ...  Show more